GnRH antagonists being modified in positions 5 and 6

US6214798A · kind A · utility

Assignee

• Ferring B.V. · NL

Inventors

• Graeme Semple · Mölndal, SE
• Guangcheng Jiang · Village of La Jolla, US

Key dates

• Filing date: Jan 3, 2000
• Grant date: Apr 10, 2001
• Expiry date: Jan 3, 2020

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y10S930/11
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Peptides are provided which have improved duration of GnRH antagonistic properties. These antagonists may be used to regulate fertility and to treat steroid-dependent tumors and for other short-term and long-term treatment indications. These antagonists have a derivative of aminoPhe or its equivalent in the 5- or the 5- and 6-positions. This derivative is modified so as to contain a carbamoyl group or heterocycle, including a urea moiety, in its side chain. Decapeptides having the formula: EQU Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(L-hydroorotyl)-D-4Amf(Q.sub. 2)-Leu-Lys(isopropyl)-Pro-Xaa.sub.10, wherein Q.sub.2 is Cbm or MeCbm and Xaa.sub.10 is D-Ala-ol or Ala-ol are particularly effective and continue to exhibit very substantial suppression of LH secretion at 96 hours following injection.